Brown/MIT team chosen for new NASA institute

PUBLIC RELEASE DATE:

6-Nov-2013

Contact: Kevin Stacey kevin_stacey@brown.edu 401-863-3766 Brown University

PROVIDENCE, R.I. [Brown University] NASA has tapped a team of Brown and MIT researchers to be part of its new Solar System Exploration Research Virtual Institute (SSERVI). The team will help to develop scientific goals and exploration strategies for the Moon, near-Earth asteroids, and the Martian moons Phobos and Deimos.

"These are the most accessible solar system targets for robotic and human exploration beyond Earth," said Carle Pieters, professor of geological sciences and principal investigator for the Brown/MIT team. "They are diverse bodies that together may hold the key to understanding the formation and evolution of our solar system."

SSERVI builds on a previous NASA Lunar Science Institute of which the Brown team was a founding member. SSERVI's mission is to facilitate collaborative scientific research relevant to NASA's exploration goals. The Brown/MIT group is one of nine selected from a pool of 32 proposals.

"We look forward to collaborative scientific discoveries from these teams," said Jim Green, director of the Planetary Science Division of NASA's Science Mission Directorate in Washington. "These results will be vital to NASA successfully conducting the ambitious activities of exploring the solar system with robots and humans."

The Brown/MIT team will focus on the environment and evolution of the exploration targets. Among the questions the researchers will explore: How did the Moon form and what processes occurred as it cooled from its early molten state? What can asteroids reveal about the origins of planets and early planetary processes? How are water and other volatiles distributed on these bodies, and what can that tell us about the evolution of volatiles in the solar system?

The team that will address those questions consists of 19 Brown faculty members, seven from MIT, and researchers from four other institutions and seven foreign countries. Maria Zuber, who earned her Ph.D. from Brown, will lead the effort on the MIT side.

The research questions the team will explore each present new exploration challenges. One of the goals of the Brown/MIT team is to approach those challenges through "science and engineering synergism."

Follow this link:

Brown/MIT team chosen for new NASA institute

NASA, ESA Spacecraft Clean Rooms Infested With Rare Bacterium

November 7, 2013

Image Caption: A microbiologist collects a swab sample from the floor of a spacecraft assembly clean room at NASA's Jet Propulsion Laboratory. Samples such as this are taken frequently during the assembly of a spacecraft and analyzed for a census of the types and numbers of microbes present in the clean room. Credit: NASA/JPL-Caltech

Lee Rannals for redOrbit.com Your Universe Online

Fewer microbes live in a spacecraft clean room than in almost any other environment on Earth. Surveys of what might be living in these clean rooms are important for understanding what could be hitching a ride into space.

With that said, NASA has announced that scientists recently discovered a rare microbe in two spacecraft clean rooms one in Florida and another in South America.

If scientists were ever to discover extraterrestrial life then it would be readily checked against the census of a few hundred types of microbes detected in spacecraft clean rooms in order to determine whether it is actually a discovery or just contamination.

NASA said microbes that are found inside these clean rooms are able to withstand stressors like drying, chemical cleaning, ultraviolet treatment and lack of nutrients. They are also able to withstand spacecraft sterilization methodologies like heating and peroxide treatment.

We want to have a better understanding of these bugs, because the capabilities that adapt them for surviving in clean rooms might also let them survive on a spacecraft, stated microbiologist Parag Vaishampayan, of NASAs Jet Propulsion Laboratory, Pasadena, California. This particular bug survives with almost no nutrients.

The space agency said that this new microbe, known as Tersicoccus phoenicis, is different from any other known bacteria. The berry-shaped bacterium has been classified as both a new species and a new genus.

Other microbes have also been discovered in a spacecraft clean room and found nowhere else on Earth. However, none of these other microbes have been discovered in two different clean rooms and nowhere else. The Tersicoccus phoenicis microbes were found 2,500 miles apart in a NASA facility at Kennedy Space Center and a European Space Agency facility in Kourou, French Guiana.

Read more from the original source:

NASA, ESA Spacecraft Clean Rooms Infested With Rare Bacterium

Here Are All The Planets NASA's Kepler Has Discovered So Far (VIDEO)

NASA is on a planet-hunting mission, and it hasn't failed to deliver.

This week the space agency announced that its Kepler spacecraft has discovered what could be 833 new planets since January, bringing its total up to 3,538 potential planets. In case that count may be a bit hard to imagine, NASA put together an animation (above) illustrating all the planets Kepler has discovered so far.

Created by Kepler's Daniel Fabrycky, the video is the third visualization of its kind to depict extrasolar planets spotted by the space telescope.

As Fabrycky explains in a description of the video on YouTube, the animation shows the "relative sizes of the orbits and planets in the multi-transiting planetary systems discovered by Kepler up to Nov. 2013."

Various colors are used to differentiate each planet orbiting its specific star, while the size of each ring the colored circles travel along equates to the size of the planet's orbit. The 7-planet system KOI-351 is the most colorful in the animation -- can you spot it?

NASA launched the Kepler spacecraft into orbit in 2009. Its aim has been to catalog celestial bodies that orbit stars in the Milky Way in hopes of finding more Earth-like planets.

As it turns out, habitable planets similar to Earth are far more common than previously thought. A study published Monday revealed that one in five sunlike stars observed by Kepler have an orbiting planet in the "habitable zone," suggesting that extraterrestrial life may exist in our own galaxy.

Also on HuffPost:

Original post:

Here Are All The Planets NASA's Kepler Has Discovered So Far (VIDEO)

NASA Education Offers Career Program for Texas High School Scholars

NASA is offering high school juniors in Texas an opportunity to explore their interests in space exploration and careers through the High School Aerospace Scholars (HAS) program.

Nominated by Texas state legislators, selected participants will engage in online forums focusing on science, technology, engineering and mathematics (STEM) topics and complete activities focused on space missions, the International Space Station, the moon, Mars and beyond to qualify for a six-day summer experience at NASA,s Johnson Space Center in Houston.

During the summer experience, students will work on a team-oriented Mars exploration project with a Texas teacher and a NASA engineer or scientist mentor. Students may receive a science elective credit toward graduation upon successful completion of the project.

To be eligible, students must be U.S. citizens, residents of Texas and high school juniors with an interest in STEM studies. Students also must have access to the Internet and e-mail, and be able to commit to the program for one year.

HAS is sponsored by NASA and funded by the State of Texas, Houston Livestock Show and Rodeo and the Rotary NASA, at no cost to the participants. The program was developed in 1999 to encourage more students to pursue studies and careers in STEM. More than 7,000 students from across Texas have participated to date.

The deadline is approaching quickly. Visit the High School Aerospace Scholars website for more information:

http://has.aerospacescholars.org/

To apply, visit:

http://has.aerospacescholars.org/apply

Please follow SpaceRef on Twitter and Like us on Facebook.

Read the original:

NASA Education Offers Career Program for Texas High School Scholars

NASA Invites Children, Families to Learn About NASA's Tracking and Data Relay Satellite

NASA's Goddard Space Flight Center Visitor Center in Greenbelt, Md., will host this month's Sunday Experiment on Nov. 17 from 1 p.m. to 3 p.m. EST. It's a free afternoon for elementary-aged school children and their families with a look at how NASA explores space and studies Earth from space using satellites and other technology.

This month's Sunday Experiment will explore NASA's Tracking and Data Relay Satellite project. The TDRS project at NASA Goddard is building three new Tracking and Data Relay Satellites: TDRS K, L and M. Ten TDRS spacecraft are currently in geosynchronous orbit. Together they form the space-based communication relay network known as the Space Network (SN).

The SN is made up of seven TDRS spacecraft that are responsible for relaying more than 40 different spacecrafts' data to the ground 24 hours a day, seven days a week. The TDRS constellation is responsible for gathering data from low-Earth orbiting spacecraft such as the Hubble Space Telescope, NASA's Earth-observing fleet of satellites and the International Space Station, and transmitting it to TDRS ground terminals. Once the data arrives at the ground terminals, it is sent out to the spacecraft's data processing facilities across the country. The communication also works the opposite direction with controllers on the ground using the SN to send commands like "Hey, satellite, turn your camera on!" to spacecraft.

TDRS K was the first of the third generation of TDRS satellites and launched Jan. 30, 2013. TDRS L, the second go this generation to launch, will launch January 2014. This generation of TDRS will ensure that NASA's communication needs are met for many years to come.

In addition to celebrating all things science, technology, engineering and mathematics, the Sunday Experiment celebrates major science missions that are managed by NASA Goddard and set to launch in the near future. The Sunday Experiment is a place where children and adults alike can discover the excitement of Goddard through fun and engaging activities.

The Sunday Experiment, usually held the third Sunday of each month from September through May, with some exceptions, spotlights Goddard's world-renowned science and engineering research and technological developments. Families leave inspired by the activities, wowed by the scientists and engineers, and excited about Goddard's revolutionary research and technology.

For more information and directions to the NASA Goddard Visitor's Center, visit:

http://www.nasa.gov/centers/goddard/visitor/home/index.html

http://www.nasa.gov/centers/goddard/visitor/directions/index.html

Please follow SpaceRef on Twitter and Like us on Facebook.

Visit link:

NASA Invites Children, Families to Learn About NASA's Tracking and Data Relay Satellite

Release of NASA Space Technology SpaceTech-REDDI-2014 NRA

The National Aeronautics and Space Administration (NASA) Headquarters, Space Technology Mission Directorate (STMD) has released an umbrella NASA Research Announcement (NRA) titled "Space Technology Research, Development, Demonstration, and Infusion 2014 (SpaceTech-REDDI-2014)". This will be STMD's inaugural umbrella solicitation covering multiple STMD programs.

The NRA is accessible from the NASA Solicitation and Proposal Integrated Review and Evaluation System (NSPIRES) website (http://nspires.nasaprs.com) by linking through the menu listing "Solicitations", and then selecting "Open Solicitations" and finally selecting "Space Technology Research, Development, Demonstration, and Infusion 2014 (SpaceTech-REDDI-2014)". Under SpaceTech-REDDI-2014, proposals will be solicited through Appendices which will be issued as funding is made available for new opportunities. Once new Appendices are released, interested parties will be able to access them by clicking through the Open Solicitations link, then selecting "NRA NNH14ZOA001N", and then selecting "List of Open Program Elements".

It is anticipated that this initial umbrella solicitation (SpaceTech-REDDI-2014) will be open for one year (through October 2014) and follow-up umbrella SpaceTech-REDDI solicitations will be issued annually in November. With every release of SpaceTech-REDDI, the NASA Space Technology Mission Directorate (STMD) will provide targeted release plans for Appendices for that year.

The STMD portfolio supports early-stage studies, for assessing the feasibility of entirely new technologies (which corresponds to a Technology Readiness Level (TRL) range from 1 to 3); matures feasible technologies through rapid competitive development and ground-based testing (TRL 3-5); and performs flight demonstrations in relevant environments to complete the final steps prior to mission infusion (TRL 5-7). This technological diversity results in a sustainable pipeline of revolutionary concepts. STMD seeks aggressive technology development efforts that may require undertaking significant technical challenges and risk to achieve a higher potential payoff.

The following STMD programs are included in the SpaceTech-REDDI-2014 umbrella NRA:

NASA Innovative Advanced Concepts (NIAC) Program focuses on visionary aeronautics and space system concepts. TRL Range: 1-3

Appendix A1: NASA Innovative Advanced Concepts (NIAC) Phase I

Appendix A2: NASA Innovative Advanced Concepts (NIAC) Phase II

Space Technology Research Grants (STRG) Program engages academia in innovative research in advanced space technology. TRL Range: 1-3

Appendix B1: Space Technology Research Grants (STRG) Early Career Faculty (ECF) Appendix B2: Space Technology Research Grants (STRG) Early Stage Innovations (ESI)

Original post:

Release of NASA Space Technology SpaceTech-REDDI-2014 NRA

NanoBio Systems Successfully Measures Glucose in Saliva Using Nanotechnology-Based Sensor

MARION, MA--(Marketwired - Nov 7, 2013) - NanoBio Systems (NBS), a medical sensor startup company, announces the successful measurement of glucose in saliva of human test subjects using a disposable nanotechnology-based sensor platform and simple, portable electronics. Limited testing has demonstrated excellent correlation with both handheld commercial glucometers and sophisticated laboratory instruments well within the FDA's required measurement tolerances.

This breakthrough could put pain-free glucose testing within the reach of every diabetic and practitioner.

The patent-pending sensor is formed using a small nanotechnology platform matched to widely accepted and FDA-approved common enzyme chemistry. The enzyme is an oxido-reductase that catalyzes the oxidation of glucose, which is then sensed by the nanotechnology platform. Plans are underway to conduct broader clinical trials prior to seeking FDA approval as a screening and monitoring device.

NBS is a technology development company pursuing innovative, proven applied engineering solutions to develop biochemical sensors for personal health care monitoring.

Read more:

NanoBio Systems Successfully Measures Glucose in Saliva Using Nanotechnology-Based Sensor

Research and Markets: Global Personalized Medicine Market to 2016: Abbott, AstraZeneca, F. Hoffman-La Roche, Novaris …

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/24c5v2/future_prospects) has announced the addition of the "Future Prospects of Global Personalized Medicine Market 2012-2016" report to their offering.

The Global Personalized Medicine market 2012-2016 to grow at a CAGR of 12.07 percent over the period 2012-2016.

One of the key drivers in this market is the significant growth of the Targeted Biologics segment. This segment is one of the significant segments of personalized medicine and is expected to signify about 25 percent of the commercialized drugs during the forecast period.

Over the years, the Global Personalized Medicine market has been witnessing the emergence of various tools and technologies from the reputed vendors. For instance, AssureRx Health Inc. launched GeneSightRx ADHD in May 2012, a personalized medicine test for the growing number of children and adults diagnosed with ADHD. Moreover, Bristol-Myers Squibb Co. collaborated with MMRF in December 2012 for advanced personalized medicine for multiple Myeloma. Further, Alacris Theranostics GmbH entered into an agreement with GlaxoSmithKline plc in November 2012 to use ModCell system for early stage cancer research. Further, AltheaDx Inc. launched FLT3 Mutation Assay in October 2012. Agendia N.V. launched ColoPrint microarray-based 18-gene expression signature in June 2012 for predicting the risk of distant recurrence for stage II colon cancer patients. The European Medicines Agency approved Zelboraf, manufactured by F. Hoffmann-La Roche Ltd., in December 2011.

Further, the report states that one of the major challenges is patients' limited awareness about personalized medicines in developing countries. Most of the patients in developing countries such as India and China are not fully aware of the recent developments in personalized medicines.

The key vendors dominating this space include:

Key Topics Covered:

01. Executive Summary

02. List of Abbreviations

Read more here:

Research and Markets: Global Personalized Medicine Market to 2016: Abbott, AstraZeneca, F. Hoffman-La Roche, Novaris ...

Foundation Medicine is part of an effort to advance new clinical trial design in lung cancer

By Chris Reidy/Globe Staff/November 7, 2013

Foundation Medicine Inc., a Cambridge cancer diagnostics start-up that has attracted high-profile financial backers such as Microsoft Corp. founder Bill Gates and Russian billionaire Yuri Milner, said Thursday that it has partnered witha coalitionof groups to advancea revolutionary newclinical trialdesignfor lung cancer.

The partnership includes Friends of Cancer Researchas well asfederal health and regulatory agencies,pharmaceutical companies,multiple cooperative groups,andpatient advocacy organizations. The goal of the partnership istodevelop the clinical trial designfortheMaster Protocolstudyin patients withsquamous cell carcinoma of the lung,acommon subtype of non-small cell lung cancer, the leading cancer killer of men and women in the US, the company said in a press release.

In a statement, Ellen V. Sigal, chairperson and founder of Friends of Cancer Research, said: FoundationMedicines comprehensive genomic platform is a critical component of the trial design, which requires the ability to identify all classes of genomic alterations across many different genes from one patient tissue sample, which ultimately informs the drug or drugs each patient will receive in the trial. This revolutionary clinical trial will provide a new perspective on our current system, saving time, money and lives. Our vision is that the concept and design of the Master Protocol study will serve as a model for future trials to accelerate the way new targeted therapies are developed and moved through the regulatory process to patients.

Copyright 2013 Globe Newspaper Company.

Read the original here:

Foundation Medicine is part of an effort to advance new clinical trial design in lung cancer

Foundation Medicine Partners with Broad-based Coalition to Advance Revolutionary New Clinical Trial Design in Lung …

CAMBRIDGE, Mass.--(BUSINESS WIRE)--

Foundation Medicine, Inc. (FMI) today announced that it has partnered with Friends of Cancer Research, as well as federal health and regulatory agencies, pharmaceutical companies, multiple cooperative groups and patient advocacy organizations to develop the clinical trial design for the Master Protocol study in patients with squamous cell carcinoma of the lung, a common subtype of non-small cell lung cancer, the leading cancer killer of men and women in the United States1. The Master Protocol is a biomarker-driven, multi-drug, multi-arm, multi-center Phase 2/3 registration trial, in which a comprehensive genomic testing platform will be used for all patients to determine stratification into appropriate target-specific arms of the trial. Foundation Medicines fully informative genomic profile has been selected as the common platform in the Master Protocol to inform the investigational targeted therapy each patient will receive based on the molecular alterations present in their tumor.

Vincent Miller, M.D., chief medical officer at Foundation Medicine, will participate in a panel session today at the 2013 Friends-Brookings Conference on Clinical Research in Washington, D.C. to discuss the activation of the Master Protocol study and present final plans to begin enrolling patients in the trial in 2014. The panel also features leaders from key collaborators in the Master Protocol study, including: Friends of Cancer Research; National Cancer Institute; Foundation for the National Institute of Health; U.S. Food & Drug Administration; and SWOG member institutions Yale Cancer Center, MD Anderson Cancer Center, University of California Davis Cancer Center, University of Colorado Cancer Center and Fred Hutchison Cancer Center.

We are excited to partner with leadership from some of our countrys most innovative public and private organizations to advance the Master Protocol study and ultimately modernize the future of oncology clinical trials, stated Ellen V. Sigal, Ph.D., chairperson and founder, Friends of Cancer Research. Foundation Medicines comprehensive genomic platform is a critical component of the trial design, which requires the ability to identify all classes of genomic alterations across many different genes from one patient tissue sample, which ultimately informs the drug or drugs each patient will receive in the trial. This revolutionary clinical trial will provide a new perspective on our current system, saving time, money and lives. Our vision is that the concept and design of the Master Protocol study will serve as a model for future trials to accelerate the way new targeted therapies are developed and moved through the regulatory process to patients.

It is challenging to recruit patients into clinical trials; the recruitment stage adds to the lengthy timeframes we currently face to bring investigational new drugs through the development process, said Roy S. Herbst, M.D. Ph.D., Ensign professor and chief of medical oncology, Yale Cancer Center and Smilow Cancer Hospital at Yale-New Haven, associate director for translational research, and clinical research program leader, Thoracic Oncology Program, Yale Cancer Center. Another key feature of the Master Protocol study is that all cooperative groups will work together to enable rapid patient accrual and screen approximately 6,000 lung cancer patients over five years. The trial is designed with the ultimate goal of FDA approval for those drugs that meet pre-specified efficacy criteria, which has the potential to address the significant unmet need for new treatment options for patients with lung cancer.

The Master Protocol study is designed to address current issues in oncology drug development by bringing multiple investigational targeted therapies into one study under a single protocol to improve the efficiency, costs and success rates associated with moving investigational new drugs through the clinical development process, and ultimately expedite the timelines in which new treatment options are available to the patients who are most likely to benefit. Using a comprehensive genomic profile maximizes the amount of genomic information that can be obtained from a single patient tissue sample, and in turn, maximizes the likelihood that individuals will be successfully matched to a targeted therapy arm. It also reduces the need for pharmaceutical companies to use time and resources to identify a specific diagnostic partner to continue development of a targeted therapy.

There is a fundamental shift in cancer care in which treatment options are informed by the molecular alterations driving a patients cancer rather than solely from the anatomic site of origin, stated Dr. Miller. Many new therapies in development are targeting alterations that are present in small percentages of patients, making it critical to confirm that the right patients are enrolled in a clinical trial to enhance the likelihood of success in the study and improve patient outcomes. To truly enable precision medicine in oncology, cancer patients must have broad access to comprehensive genomic testing in routine clinical care are well as oncology clinical trials, and we believe the Master Protocol study is an innovative step forward in this direction.

About Foundation Medicine

Foundation Medicine (FMI) is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient's unique cancer. The company's initial clinical assay, FoundationOne, is a fully informative genomic profile to identify a patient's individual molecular alterations and match them with relevant targeted therapies and clinical trials. Foundation Medicine's molecular information platform aims to improve day-to-day care for patients by serving the needs of clinicians, academic researchers and drug developers to help advance the science of molecular medicine in cancer. For more information, please visit http://www.FoundationMedicine.com or follow Foundation Medicine on Twitter (@FoundationATCG).

Foundation Medicineis a registered trademark, and FoundationOne, is a trademark of Foundation Medicine, Inc.

Continued here:

Foundation Medicine Partners with Broad-based Coalition to Advance Revolutionary New Clinical Trial Design in Lung ...

Foundation Medicine Announces 2013 Third Quarter Results

CAMBRIDGE, Mass.--(BUSINESS WIRE)--

Foundation Medicine, Inc. (FMI) today announced that 2,577 FoundationOne tests were reported to ordering oncologists in the quarter ended September 30, 2013, an increase from the 1,626 reported in the second quarter of 2013. Total revenues increased to $8.2 million for the third quarter of 2013 compared with $5.9 million in the second quarter of 2013. More than half of third quarter revenues were derived from clinical testing. FoundationOne, the companys initial clinical product, is a fully informative genomic profile used by oncologists to identify a patients individual molecular alterations and match them with relevant targeted therapies and clinical trials.

Results in the third quarter demonstrate the growing enthusiasm in the marketplace for our fully informative genomic profile for use across all solid tumors, said Michael Pellini, M.D., president and chief executive officer, Foundation Medicine. We are very encouraged by the commercial traction as the utility of FoundationOne and the information it delivers garners growing recognition among oncologists, pathologists and pharmaceutical companies. In addition, the number of scientific publications generated using our molecular information platform during the quarter continues to underscore its clinical utility and value in the care of patients with cancer.

Total operating expenses for the third quarter of 2013 were $16.5 million, inclusive of $3.0 million in stock-based compensation expense. This compares with total operating expenses for the second quarter of 2013 of $13.7 million, inclusive of $1.3 million in stock-based compensation expense. In addition to stock-based compensation expense, the increase in operating expenses was primarily attributable to the ongoing development of FoundationOne for hematologic malignancies, relocation costs of moving to a new headquarters facility and the growth of our commercial organization.

Net loss was $12.5 million in the third quarter of 2013, inclusive of a $1.3 million warrant remeasurement charge, or a $3.51 loss per basic and diluted share. At September 30, 2013, the company had $138 million of cash, cash equivalents and investments.

Third Quarter and Recent Enterprise Highlights

Conference Call and Webcast Details

To access the live conference call today, November 6 at 4:30 p.m. Eastern Time via phone, dial (877) 941-2069 from the United States and Canada or +1(480) 629-9713 internationally and reference Foundation Medicine providing the passcode 4647488. Dial in approximately ten minutes prior to the start of the call. The live, listen-only webcast of the conference call can be accessed by visiting the investors section of the Foundation Medicine website at investors.foundationmedicine.com. A replay of the webcast will be available shortly after the conclusion of the call and archived on the companys website for two weeks following the call.

About Foundation Medicine

Foundation Medicine (FMI) is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patients unique cancer. The companys initial clinical product, FoundationOne, is a fully informative genomic profile to identify a patients individual molecular alterations and match them with relevant targeted therapies and clinical trials. Foundation Medicines molecular information platform aims to improve day-to-day care for patients by serving the needs of clinicians, academic researchers and drug developers to help advance the science of molecular medicine in cancer. For more information, please visit http://www.foundationmedicine.com or follow Foundation Medicine on Twitter (@FoundationATCG).

More here:

Foundation Medicine Announces 2013 Third Quarter Results

Security and liberty: William ‘Pat’ Schuber at TEDxFairleighDickinsonUniversity – Video


Security and liberty: William #39;Pat #39; Schuber at TEDxFairleighDickinsonUniversity
"Security and Liberty: Is Big Brother Alive and Well?" This TED Talk will examine the issue of the delicate balance between security and liberty by examining...

By: TEDxTalks

Go here to read the rest:

Security and liberty: William 'Pat' Schuber at TEDxFairleighDickinsonUniversity - Video

LEGO Marvel Super Heroes – Liberty Gameplay + Free Roam (Statue of Liberty Character) – Video


LEGO Marvel Super Heroes - Liberty Gameplay + Free Roam (Statue of Liberty Character)
I had a request to show some gameplay with the Statue of Liberty character named "Liberty". She doesn #39;t really have much of an arsenal other than kicking and...

By: packattack04082

Link:

LEGO Marvel Super Heroes - Liberty Gameplay + Free Roam (Statue of Liberty Character) - Video

Grand Theft Auto 3: Liberty Stories – Gameplay Review Game Trailer Walkthrough [PlayStation Vita] – Video


Grand Theft Auto 3: Liberty Stories - Gameplay Review Game Trailer Walkthrough [PlayStation Vita]
Check out the Playstation Vita Games Playlist - http://www.youtube.com/playlist?list=PL8wZKON07iXUYb3LMM41CFpjsJ65SRIJu Grand Theft Auto: Liberty City Storie...

By: iGameplay1337

Read the original here:

Grand Theft Auto 3: Liberty Stories - Gameplay Review Game Trailer Walkthrough [PlayStation Vita] - Video

Denver-based Liberty II announces $350 million commitment

Liberty Resources II LLC, a newly formed Denver-based oil-and-gas company, announced Thursday a $350 million commitment, including $300 million from funds managed by energy equity firm Riverstone Holdings LLC, $50 million from Oakmont Corp. and additional amounts from the company's management team.

Riverstone and Liberty II management previously partnered in Liberty Resources LLC, an oil-and-gas company focused on the Bakken Shale of North Dakota.

The company said that after its formation, Liberty established a land position of about 43,000 net acres and drilled and completed 29 operated wells in the Bakken Shale and Three Forks formations of North Dakota. The majority of Liberty's assets were sold to Kodiak Oil & Gas in July for about $680 million.

Liberty II is led by chairman and CEO Chris Wright, president Mark Pearson, chief financial officer Paul Vitek and other former executives of Liberty.

Among potential areas of focus, Liberty II will likely concentrate its efforts in the Denver-Julesberg Basin, the Powder River Basin and the Permian Basin, said the company.

Howard Pankratz: 303-954-1939, hpankratz@denverpost.com or twitter.com/howardpankratz

See more here:

Denver-based Liberty II announces $350 million commitment

Liberty Global Misses on Q4 Earnings

Liberty Global plc. (LBTYA) declared disappointing financial results for the third quarter of 2013 as both the top and bottom line significantly lagged the respective Zacks Consensus Estimates. In the reported quarter, the company added 314,000 organic revenue generating units (:RGU), down 1.9% year over year.

Quarterly GAAP net loss was $830.1 million or $2.09 per share compared with a net loss of $22.4 million or 8 cents per share in the prior-year quarter. However, adjusted earnings per share of 9 cents were substantially below the Zacks Consensus Estimate of 46 cents. Quarterly total revenue of $4,371.2 million was up 73.5% year over year, but fell below the Zacks Consensus Estimate of $4,422 million.

Cost of operations was $1,702.9 million, up 98.2% year over year. Operating income was $521.9 million, down 2.5% year over year. Operating margin was 11.9% compared with 20.2% in the year-ago quarter.

During the first nine months of 2013, Liberty Global generated $2,466 million of cash from operations compared with $1,886.2 million in the year-ago period. Free cash flow in the reported period was $665.8 million against $435.5 million in the prior-year quarter.

At the end of the third quarter of 2013, Liberty Global had $5,513.6 million of cash and marketable securities and $43,147.6 million of outstanding debt on its balance sheet compared with $2,989 million and $27,524.5 million, respectively, at the end of 2012.

Subscriber Statistics

As of Sep 30, 2013, Liberty Global had a total of 24,473,800 customers. Out of the total, customer count for European Operations, VTR and Other operations were 23.009 million, 1.1938 million and 0.271 million, respectively. The total Single-Play customer count was 10.825 million, which remained same year over year. The total Double-Play customer count was 3.924 million, up 32.4% year over year. The total Triple-Play customer count was 9.7248 million, up 67.8% year over year.

During the reported quarter, Liberty Global added 314,000 organic RGUs including net gains of 214,000 and 153,000 subscribers for broadband Internet and telephony services respectively, and a net loss of 53,000 subscribers for video services. At quarter end, the company had over 365,000 Horizon TV subscribers in the Netherlands, Switzerland, Ireland and Germany. Liberty Global had more than 1.8 million TiVo Inc. (TIVO)-platform based video subscribers with a quarterly net addition of 165,000 subscribers. Moreover, the company had 4.05 million mobile subscribers.

Segment-wise Results

Total revenue from the European Operations division was $3,947.8 million, up 83.7% year over year. Within this segment, revenues from Western Europe were $3,635.3 million, up 96.9% year over year. Revenues from Central and Eastern Europe were $279.1 million, up 1.9% year over year. Revenues from Central and other operation were $33.4 million, up 15.2% year over year. VTR Chile revenues were $244.8 million, up 1.6% year over year. Corporate and other revenues were $199.8 million, up 32.9% year over year.

Read the original post:

Liberty Global Misses on Q4 Earnings